Names Board of Directors
SAN DIEGO, Jan. 31 /PRNewswire/ -- Sonexa Therapeutics, Inc., a clinical-stage biopharmaceutical company developing therapeutics for the treatment of Alzheimer's disease, announced today that it has raised $30 million in a Series A round of financing. The financing was led by Domain Associates, L.L.C., Scale Venture Partners and Alta Partners. Additional investors included AgeChem Venture Fund, and MC Life Science Ventures. Sonexa also announced the appointment of its Board of Directors. Sonexa founding CEO Eckard Weber, M.D., will serve as Chairman. Weber, a Partner with Domain Associates, is a founding CEO of more than a dozen biopharmaceutical companies. Additional Directors include Kim Puloma Kamdar, Ph.D., of Domain Associates, Lou Bock, a Managing Director with Scale Venture Partners, and Robert Alexander, Ph.D., with Alta Partners. The management team includes president and CMO Sharon Rogers, Ph.D., who played a leading role in developing Aricept, the top-selling Alzheimer's medication.
Proceeds from the financing will be used to fund the licensing and development of a novel drug being tested as a therapeutic to treat Alzheimer's disease. Sonexa has licensed worldwide, exclusive rights (except for Japan and certain Asian countries) to the compound from a Japanese pharmaceutical company. Human trials in the US are scheduled to begin February '08.
About Domain Associates
Founded in 1985, Domain Associates, L.L.C. is a venture capital firm
with an exclusive focus on life sciences. With $2.1 billion of capital
under management, Domain is headquartered in Princeton, NJ with a second
office in San Diego, CA. Domain's three major investment segments are
pharmaceuticals, specialty pharmaceuticals, and medical devices, while
additional areas of interest include biomaterials, bioinstrumentation, and
diagnostics. The Partners of Domain have a total of close to 200
person-years of experienc
|SOURCE Sonexa Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved